Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.

The Lancet. Oncology - 1 Mar 2021

Gibson Joanna A, Finberg Karin E, Nalbantoglu ILKe, Cecchini Michael, Ganzak Amanda, Walther Zenta, Sklar Jeffrey L, Eder Joseph P, Goldberg Sarah B

Abstract excerpt

No abstract is available from the source.

Topics

Adenocarcinoma
Biomarkers, Tumor
Diagnosis, Differential
Gallbladder Neoplasms
High-Throughput Nucleotide Sequencing
Humans
Male
Mesothelioma
Middle Aged
Molecular Targeted Therapy
Mutation
Patient Care Planning
Peritoneal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Precision Medicine

Prognosis

Source

Identifiers

PMID: 33662283
DOI: 10.1016/S1470-2045(20)30683-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.PMID 33662283Read ↗

Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.Semantic proximity Read ↗

Special report: multiple molecular testing of cancers to identify targeted therapies.Semantic proximity Read ↗

Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.Semantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health systemSemantic proximity Read ↗

Molecular profiling for precision cancer therapiesSemantic proximity Read ↗

[Molecular diagnostics in oncology].Semantic proximity Read ↗

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsSemantic proximity Read ↗

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.Semantic proximity Read ↗

Next-Generation Sequencing in Oncology in the Era of Precision Medicine.Semantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.